Diagnostic Values of Serum Total Prostate-Specific Antigen for Detection of Breast Masses Nature in 20-75-Year-Old Women with Breast Mass

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of General Surgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Radiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Resident, Department of General Surgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Previous studies had shown that patients with breast cancer have a high level of prostate-specific antigen (PSA). But there was not any study about the role of prostate-specific antigen in detection of breast cancer. So, this study was done to determine the diagnostic values of prostate-specific antigen in detection of breast masses nature.Methods: In a cross sectional study, 100 patients with breast mass candidate for biopsy were selected and serum level of total serum prostate-specific antigen was measured. Then, patients underwent biopsy and diagnostic values were calculated for it in comparison with pathology results.Findings: The cut point of prostate-specific antigen for detection of breast mass nature was 0.21 ng/dl and according to it, sensitivity and specificity of prostate-specific antigen was 88.5 and 98.6 percent, respectively. False negative and positive was 1.4 and 11.5 percent, respectively. In addition, positive and negative predictive values were 95.8 and 96.1 percent, respectively, and accuracy rate of prostate-specific antigen was 96 percent.Conclusion: According to our findings, prostate-specific antigen have a high diagnostic value for detection of breast mass nature and it can be used as a serum biomarker to detect the nature of breast mass, especially in early stages.

Keywords

References

  1. Lieu D. Value of cytopathologist-performed ultrasound-guided fine-needle aspiration as a screening test for ultrasound-guided core-needle biopsy in nonpalpable breast masses. Diagn Cytopathol 2009; 37(4): 262-9.
  2. Kooistra B, Wauters C, Strobbe L. Indeterminate breast fine-needle aspiration: repeat aspiration or core needle biopsy? Ann Surg Oncol 2009; 16(2): 281-4.
  3. Lieu D. Cytopathologist-performed ultrasound-guided fine-needle aspiration and core-needle biopsy: a prospective study of 500 consecutive cases. Diagn Cytopathol 2008; 36(5): 317-24.
  4. Usami S, Moriya T, Kasajima A, Suzuki A, Ishida T, Sasano H, et al. Pathological aspects of core needle biopsy for non-palpable breast lesions. Breast Cancer 2005; 12(4): 272-8.
  5. Yang JH, Lee WS, Kim SW, Woo SU, Kim JH, Nam SJ. Effect of core-needle biopsy vs fine-needle aspiration on pathologic measurement of tumor size in breast cancer. Arch Surg 2005; 140(2): 125-8.
  6. Oyama T, Koibuchi Y, McKee G. Core needle biopsy (CNB) as a diagnostic method for breast lesions: comparison with fine needle aspiration cytology (FNA). Breast Cancer 2004; 11(4): 339-42.
  7. Medina-Franco H, Abarca-Perez L, Cortes-Gonzalez R, Soto-Germes S, Ulloa JA, Uribe N. Fine needle aspiration biopsy of breast lesions: institutional experience. Rev Invest Clin 2005; 57(3): 394-8. [In Spanish].
  8. Nassar A. Core needle biopsy versus fine needle aspiration biopsy in breast--a historical perspective and opportunities in the modern era. Diagn Cytopathol 2011; 39(5): 380-8.
  9. Kooistra B, Wauters C, Strobbe L, Wobbes T. Preoperative cytological and histological diagnosis of breast lesions: A critical review. Eur J Surg Oncol 2010; 36(10): 934-40.
  10. Rao R, Lilley L, Andrews V, Radford L, Ulissey M. Axillary staging by percutaneous biopsy: Sensitivity of fine-needle aspiration versus core needle biopsy. Ann Surg Oncol 2009; 16(5): 1170-5.
  11. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003; 21(2): 383-91.
  12. Prins GS, Chan P. What is the prostate and what are its functions? In: Robaire B, Chan P, editors. Andrology Handbook. 2nd ed. Schaumburg, IL: American Society of Andrology; 2010. p. 1-4.
  13. Mashkoor FC, Al-Asadi JN, Al-Naama LM. Serum level of prostate-specific antigen (PSA) in women with breast cancer. Cancer Epidemiol 2013; 37(5): 613-8.
  14. Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Levesque MA, et al. Prostate-specific antigen in serum of women with breast cancer. Br J Cancer 1995; 72(3): 728-31.
  15. Yu H, Diamandis EP, Levesque M, Giai M, Roagna R, Ponzone R, et al. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 1996; 40(2): 171-8.
  16. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJ, Levesque MA, et al. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 1995; 55(10): 2104-10.
  17. Yu H, Berkel H. Prostate-specific antigen (PSA) in women. J La State Med Soc 1999; 151(4): 209-13.
  18. Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, van Putten WL, et al. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br J Cancer 1999; 79(5-6): 888-94.
Journal of Isfahan Medical School
Volume 35, Issue 439 - Serial Number 439
May and June 2017
Pages 870-875

Files

History

  • Receive Date: 19 June 2017
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics